| Drug Name |
Apixaban |
| Drug ID |
BADD_D00151 |
| Description |
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. |
| Indications and Usage |
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897]. |
| Marketing Status |
approved |
| ATC Code |
B01AF02 |
| DrugBank ID |
DB06605
|
| KEGG ID |
D03213
|
| MeSH ID |
C522181
|
| PubChem ID |
10182969
|
| TTD Drug ID |
D0I5HF
|
| NDC Product Code |
0003-0893; 52048-0420; 69037-0023; 76397-007; 15308-1221; 24196-190; 58032-2028; 66174-0091; 50193-0893; 65372-1196; 65727-081; 0003-3764; 55154-0612; 59651-051; 70366-001; 14445-149; 12783-0893; 12783-0894; 17381-026; 42765-025; 42816-0894; 58623-0137; 63850-8085; 65129-1344; 66039-925; 66651-921; 69989-0006; 63629-7747; 12658-0440; 53869-0893; 73377-191; 55154-0613; 70518-1861; 71610-662; 67835-0015; 75945-060; 76397-010; 50090-6454; 82982-054; 14501-0089; 16436-0113; 65129-1465; 63629-8432; 14445-014; 53747-062; 53869-0894; 63415-0520; 65015-897; 76072-1017; 14445-150; 42816-0893; 0003-0894; 55111-980; 50090-6451 |
| UNII |
3Z9Y7UWC1J
|
| Synonyms |
apixaban | Eliquis | BMS 562247 | BMS562247 | BMS-562247-01 | BMS-562247 |
